New study tracks Dupilumab's Real-World impact on esophagitis patients
NCT ID NCT06695897
First seen Mar 15, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study follows 150 adults with eosinophilic esophagitis (EoE) who are starting dupilumab as part of their normal medical care in Germany. Researchers will collect information on patients' medical history, symptoms, quality of life, and any side effects over two years. The goal is to understand how well dupilumab works in everyday practice and how it affects patients' daily lives.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 0000001
RECRUITINGDachau, Bavaria, 85221, Germany
Conditions
Explore the condition pages connected to this study.